Premium
Long‐term outcome of chronic hepatitis C virus infection in a real‐world setting: The German LOTOS study
Author(s) -
Wedemeyer Heiner,
Reimer Jens,
Sandow Petra,
Hueppe Dietrich,
Lutz Thomas,
Gruengreiff Kurt,
Goelz Joerg,
Christensen Stefan,
PfeifferVornkahl Heike,
Alshuth Ulrich,
Manns Michael P.
Publication year - 2017
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.13399
Subject(s) - medicine , hepatocellular carcinoma , decompensation , gastroenterology , cohort , prospective cohort study , ribavirin , liver transplantation , hepatitis c , cirrhosis , incidence (geometry) , clinical endpoint , hepatitis c virus , transplantation , immunology , clinical trial , virus , physics , optics
Background & Aims There are few large‐scale, prospective studies comparing liver‐associated events in treated and untreated patients with CHC managed in routine clinical practice. Methods Patients with CHC were prospectively enrolled in a non‐interventional study. Data from patients with available documentation who had either achieved a sustained virological response, or were non‐responders, relapsers, or had virological breakthrough following treatment with peginterferon alfa‐2a±ribavirin, or who had been diagnosed but never treated at least 3 years previously, and who remained under medical observation were analyzed. Primary endpoint was liver‐associated events (composite of decompensation/liver failure, ascites, hepatocellular carcinoma, or liver transplant/placement on a transplant list). Results In all, 1444 eligible patients were identified. Mean follow‐up was 4.7 (standard deviation; SD 1.1) years. Patients with sustained virological response had a lower incidence of liver‐associated events vs non‐responders, relapsers, or virological breakthrough and never treated patients (1.7% vs 4.7% and 4.7% respectively). The proportion of patients with cirrhosis increased from baseline in the non‐responders, relapsers, or virological breakthrough (6.8%‐10.5%) and never treated group (3.7%‐8.4%), with an associated increase in severity, but was unchanged in the sustained virological response group (2.1%). Event‐free survival was significantly higher in sustained virological response patients ( P =.0082). Conclusions In this “real‐world” cohort, the achievement of sustained virological response almost eliminated liver‐related morbidity and mortality compared with patients who failed to achieve sustained virological response and those who were untreated. Overall, the LOTOS cohort highlights the importance of timely and effective treatment for patients with CHC .